| Entry |
|
|---|
| Name |
Daprodustat (JAN/USAN/INN);
Duvroq (TN) |
|---|
| Formula |
C19H27N3O6
|
|---|
| Exact mass |
393.19
|
|---|
| Mol weight |
393.4342
|
|---|
| Structure |
|
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Anti-anemic, Prolyl hydroxylase inhibitor |
|---|
| Comment |
Treatment of anemia, diabetic wounds, and reduction of ischemic complications
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D10874 Daprodustat (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
HIF hydroxylase
EGLN (HPH)
D10874 Daprodustat (JAN/USAN/INN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10874
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10874
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 28
1 N1y N 25.6200 -18.9700
2 C5x C 25.6200 -20.3700
3 N1y N 26.8324 -21.0700
4 C5x C 28.0449 -20.3700
5 C1y C 28.0449 -18.9700
6 C5x C 26.8324 -18.2700
7 O5x O 24.4076 -21.0700
8 O5x O 26.8324 -16.8702
9 O5x O 29.2760 -21.0810
10 C1y C 24.4076 -18.2700
11 C1y C 26.8324 -22.4698
12 C5a C 29.2760 -18.2590
13 N1b N 30.4812 -18.9547
14 O5a O 29.2757 -16.8701
15 C1b C 31.6635 -18.2719
16 C6a C 32.8575 -18.9612
17 C1x C 24.4076 -16.8702
18 C1x C 23.1951 -16.1702
19 C1x C 21.9827 -16.8702
20 C1x C 21.9827 -18.2700
21 C1x C 23.1951 -18.9700
22 C1x C 25.6032 -23.1797
23 C1x C 25.6034 -24.5797
24 C1x C 26.8159 -25.2796
25 C1x C 28.0451 -24.5697
26 C1x C 28.0449 -23.1697
27 O6a O 34.0454 -18.2752
28 O6a O 32.8578 -20.3697
BOND 30
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 2 7 2
8 6 8 2
9 4 9 2
10 1 10 1
11 3 11 1
12 5 12 1
13 12 13 1
14 12 14 2
15 13 15 1
16 15 16 1
17 10 17 1
18 17 18 1
19 18 19 1
20 19 20 1
21 20 21 1
22 10 21 1
23 11 22 1
24 22 23 1
25 23 24 1
26 24 25 1
27 25 26 1
28 11 26 1
29 16 27 1
30 16 28 2
|
|---|
